Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1550-1556

  Ying, Xia ^a   Zhao, Yue ^b   Wang, Jun Lan ^a   Zhou, Xia ^a   Zhao, Jing ^a   He, Chen Chen ^a   Guo, Xi Jing ^a   Jin, Gui Hua ^a   Wang, Li Juan ^a   Zhu, Qing ^a   Han, Su Xia ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

Autoantibody; Biomarker; Diagnosis; Hepatocellular carcinoma; Osteopontin

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; OSTEOPONTIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER SURVIVAL; CHRONIC HEPATITIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SEROLOGY; TUMOR VOLUME; VERY ELDERLY; WESTERN BLOTTING; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS C; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84923068285     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3367     Document Type: Article

References (36)

1. Gomaa AI, Khan SA, Toledano MB, Waked I and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 14: 4300-4308, 2008.
2. Parikh S and Hyman D: Hepatocellular cancer: a guide for the internist. Am J Med 120: 194-202, 2007. (Pubitemid 46341174)
3. Behne T and Copur MS: Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012: 859076, 2012.
4. Cheng J, Wang W, Zhang Y, et al: Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PloS One 9: e87011, 2014.
5. Chen M, Li G, Yan J, et al: Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 423: 105-111, 2013.
6. Song P, Feng X, Zhang K, et al: Perspectives on using des-gamma-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr 2: 227-231, 2013.
7. Zhu Q, Liu M, Dai L, et al: Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev 12: 1123-1128, 2013.
8. Zhang Y, Ying X, Han S, et al: Autoantibodies against insulin-like growth factor binding protein-2 as a serological biomarker in the diagnosis of lung cancer. Int J Oncol 42: 93-100, 2013.
9. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108: 1411-1415, 2001.
10. Zhang JY, Chan EK, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189: 1101-1110, 1999. (Pubitemid 29169827)
11. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM and Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95: 713-724, 1995.
12. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA and Giachelli CM: Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275: 20959-20962, 2000. (Pubitemid 30481782)
13. Chen F, Liu H, Shen Q, et al: Osteopontin: participation in inflammation or mucosal protection in inflammatory bowel diseases? Dig Dis Sci 58: 1569-1580, 2013.
14. Yang M, Ramachandran A, Yan HM, et al: Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. Toxicol Lett 224: 186-195, 2014.
15. Shao JS, Sierra OL, Cohen R, et al: Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol 31: 1821-1833, 2011.
16. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD and Denhardt DT: Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269: 711-715, 1994. (Pubitemid 24026717)
17. Kawashima R, Mochida S, Matsui A, et al: Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 256: 527-531, 1999. (Pubitemid 29301139)
18. Hahne JC, Meyer SR, Kranke P, et al: Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol 189: 1040-1048, 2013.
19. Ramachandran S, Kwon KY, Shin SJ, et al: Regulatory role of osteopontin in malignant transformation of endometrial cancer. Mol Biol Rep 40: 3623-3629, 2013.
20. Li NY, Weber CE, Mi Z, Wai PY, Cuevas BD and Kuo PC: Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J Am Coll Surg 217: 17-26, 2013.
21. Yu TT, Han ZG, Shan L, Tao J, Zhang T, Yuan SF and Shen HL: Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 15: 29-32, 2014.
22. Huang J, Pan C, Hu H, Zheng S and Ding L: Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PloS One 7: e47901, 2012.
23. Righi L, Bollito E, Ceppi P, et al: Prognostic role of bone sialoprotein in clear cell renal carcinoma. Anticancer Res 33: 2679-2687, 2013.
24. Shang S, Plymoth A, Ge S, et al: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55: 483-490, 2012.
25. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA and Sayed D: Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol 10: 296-305, 2011.
26. Shao Q, Ren P, Li Y, et al : Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol 41: 1061-1067, 2012.
27. Xie H, Song J, Du R, et al: Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig liver Dis 39: 167-172, 2007. (Pubitemid 46117934)
28. Ramaiah SK and Rittling S: Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103: 4-13, 2008. (Pubitemid 351524472)
29. O'Regan AW, Nau GJ, Chupp GL and Berman JS: Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 21: 475-478, 2000.
30. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH and Cantor H: T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc Natl Acad Sci USA 102: 17101-17106, 2005. (Pubitemid 41692690)
31. Denhardt DT, Noda M, O'Regan AW, Pavlin D and Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061, 2001. (Pubitemid 32422899)
32. Cao DX, Li ZJ, Jiang XO, et al: Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol 18: 3923-3930, 2012.
33. Sun BS, Dong QZ, Ye QH, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 48: 1834-1842, 2008.
34. Philip S and Kundu GC: Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487-14497, 2003. (Pubitemid 36800002)
35. Tilli TM, Silva EA, Matos LC, et al: Osteopontin is a tumor autoantigen in prostate cancer patients. Oncol Lett 2: 109-114, 2011.
36. Sakata M, Tsuruha JI, Masuko-Hongo K, et al: Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 28: 1492-1495, 2001. (Pubitemid 32660618)